Premium
Informed consent: Patients with OUD must be told about MAT
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.33202
Subject(s) - buprenorphine , naltrexone , opioid use disorder , methadone , food and drug administration , medicine , informed consent , opioid , expanded access , methadone maintenance , family medicine , psychiatry , alternative medicine , pharmacology , receptor , pathology
When patients seek treatment, they are supposed to receive “informed consent,” but the actual rules are governed by state law, according to the Legal Action Center. We wondered about this when a recent unscientific survey of residential treatment programs showed that many do not provide buprenorphine for patients with opioid use disorder (OUD). Buprenorphine, methadone and naltrexone are the only three medications approved by the Food and Drug Administration (FDA) for the treatment of OUD, and methadone can only be provided in a federally licensed opioid treatment program (OTP). Methadone and buprenorphine are both opioids themselves, which seems to be the main objection to use of these medications.